What Factors Propelled The Growth Of The Pulmonary Arterial Hypertension Market In The Past?
The pulmonary arterial hypertension market has seen considerable growth due to a variety of factors.
• The market size for pulmonary arterial hypertension has seen significant expansion in the past few years. Projected growth indicates an increase from $8.47 billion in 2024, to $9.24 billion in 2025. This signifies a 9.1% Compound Annual Growth Rate (CAGR).
The substantial growth experienced in the prior period is due to a rise in awareness and diagnosis of pulmonary arterial hypertension (PAH), elevated spending within the healthcare sector, an aging population growth, expansion in treatment options for pulmonary arterial hypertension, and an increase in PAH-focused research and development initiatives.
What Is The Projected Growth And Market Size For The Pulmonary Arterial Hypertension Sector?
The pulmonary arterial hypertension market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated robust expansion in the next few years is predicted for the pulmonary arterial hypertension market, which is set to balloon to $12.97 billion in 2029 with a compound annual growth rate (CAGR) of 8.8%.
The uptrend during the forecast period is due to factors like the embracing of ground-breaking treatments for pulmonary arterial hypertension, greater emphasis on early detection and diagnosis, the burgeoning pipeline of drugs and therapies designed for PAH, the incorporation of precision medicine into PAH treatments, and the augmentation of health care infrastructure in emerging economies. Key trends for the forecast period encompass advancements in medical imaging and diagnostic apparatus, alliances and partnerships forged for drug evolution, a focus on patient-orientated strategies in the management of pulmonary arterial hypertension, and a surge in the utilization of combination therapy.
What Factors Are Driving Growth In The Pulmonary Arterial Hypertension Market?
The escalating occurrence of pulmonary arterial hypertension (PAH) disease is significantly influencing the progression of the pulmonary arterial hypertension market. The upward trend in PAH cases and the subsequent hospitalization of patients is speculated to stimulate the need for associated drugs throughout the projected timeline. As per a study released by the National Organization for Rare Disorders, Inc., the rates of new PAH cases are projected to be between one to two people per million annually in the USA, which corresponds to 500–1000 fresh instances per annum, and it's anticipated that Europe will have comparable rates of incidence.
What Are The Main Segments Of The Global Pulmonary Arterial Hypertension Market?
The pulmonary arterial hypertension market covered in this report is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat
Pre-Book The Pulmonary Arterial Hypertension Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Pulmonary Arterial Hypertension Market?
Leading corporations in the pulmonary arterial hypertension market are revolutionizing treatment options and patient outcomes by developing sophisticated products like Winrevair. In March 2024, the multinational pharmaceutical firm, Merck & Co. Inc., based in the United States, introduced Winrevair to treat adults diagnosed with pulmonary arterial hypertension. This ground-breaking treatment, approved by the US Food and Drug Administration (FDA), is the first of its kind to target activin signaling for pulmonary arterial hypertension (PAH). It functions by reinstating the equilibrium between pro- and anti-proliferative signals, thereby controlling the vascular cell proliferation linked to PAH. Consequently, a new therapeutic category is established for this illness.
Who Are the Key Players in the Pulmonary Arterial Hypertension Market?
Major companies operating in the pulmonary arterial hypertension market include:
• United Therapeutics Corporation
• Acceleron Pharma Inc.
• Actelion Pharmaceuticals US Inc.
• Bayer AG
• Eli Lilly and Company
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Liquidia Technologies Inc.
• Lupin Pharmaceuticals Inc.
• Natco Pharma Ltd.
• Pfizer Inc.
• Sandoz AG
• Teva Pharmaceutical Industries Ltd.
• Zydus Pharmaceutical USA Inc.
• Allegheny Health Network
• Cedars-Sinai Medical Center
• Cleveland Clinic
• Houston Methodist Hospital
• Johns Hopkins Medicine
• Massachusetts General Hospital
• Mayo Clinic
• MedStar Heart & Vascular Institute
• National Jewish Health
• NewYork-Presbyterian Hospital
• Ochsner Medical Center
• Royal Brompton & Harefield NHS Foundation Trust
• Rush University Medical Center
• Stanford Health Care
• Swedish Medical Center
• Temple University Hospital
• University of California Health.
What Is The Most Dominant Region In The Pulmonary Arterial Hypertension Market?
North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
